Free Trial
→ One executive order. The biggest wealth transfer of your lifetime. (From Reagan Gold Group) (Ad)tc pixel
NASDAQ:KYTX

Kyverna Therapeutics Q3 2024 Earnings Report

Kyverna Therapeutics logo
$9.47 +0.26 (+2.82%)
Closing price 04:00 PM Eastern
Extended Trading
$9.49 +0.02 (+0.26%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Kyverna Therapeutics EPS Results

Actual EPS
-$0.80
Consensus EPS
-$0.81
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Kyverna Therapeutics Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kyverna Therapeutics Announcement Details

Quarter
Q3 2024
Date
11/13/2024
Time
After Market Closes
Conference Call Date
Wednesday, November 13, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Kyverna Therapeutics' Q1 2026 earnings is estimated for Tuesday, May 12, 2026, based on past reporting schedules, with a conference call scheduled on Monday, May 11, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Kyverna Therapeutics' Q3 2024 Press ReleasePress Release
(8-K)
Kyverna Therapeutics' Q3 2024 Quarterly reportQuarterly report
(10-Q)

Kyverna Therapeutics Earnings Headlines

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Average Recommendation of "Moderate Buy" by Analysts
May 6 at 2:37 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30760691
Kyverna Therapeutics Appoints Chief Commercial Officer for Growth
May 4 at 8:51 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/kyverna-therapeutics-appoints-chief-commercial-officer-for-growth?utm_source=marketbeat.com&utm_medium=referral
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
May 6 at 1:00 AM  |  Reagan Gold Group (Ad)
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
May 4 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/04/3286654/0/en/kyverna-therapeutics-appoints-nadia-dac-seasoned-commercial-leader-in-neurology-and-rare-disease-as-chief-commercial-officer.html
Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis
April 22, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4893015-kyverna-therapeutics-strong-buy-on-additional-poc-of-miv-cel-in-myasthenia-gravis
Kyverna Shares Rise Premarket After Promising Trial of Neurological Product
April 22, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/kyverna-shares-rise-premarket-after-promising-trial-of-neurological-product-11a20519
See More Kyverna Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kyverna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kyverna Therapeutics and other key companies, straight to your email.

About Kyverna Therapeutics

Kyverna Therapeutics (NASDAQ:KYTX) is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions. Kyverna’s approach centers on scalable manufacturing processes and precision cell engineering, enabling the production of off‐the‐shelf therapeutic products with defined dosing and predictable pharmacology. Collaborations with academic institutions and biotech partners support its pipeline advancement and translational research efforts.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Kyverna Therapeutics draws on a leadership team with deep expertise in cell therapy, immunology and bioprocess development. The company operates research and manufacturing facilities in the Greater Boston area and engages with regulatory authorities in North America and Europe to advance its clinical programs. Kyverna’s strategic vision is to pioneer durable, disease‐modifying treatments that address high‐unmet needs in autoimmune and inflammatory disorders.

View Kyverna Therapeutics Profile
Earnings Tools